← Eichor
Study identifier: NCT07563205 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer · Non Small Cell Lung Cancer Metastatic · Non Small Cell Lung Cancer NSCLC  ·  Sponsor: GFPC Investigation

PhaseN/A
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this observational study is to understand how well a treatment combining chemotherapy and amivantamab works in real life, and how safe it is, in adults with metastatic non-small cell lung cancer (NSCLC) who have certain EGFR gene mutations. The study includes two groups of people: * Group A: people with an EGFR exon 20 insertion who receive amivantamab together with platinum-based chemotherapy as their first treatment, through an early access program. * Group B: people with an EGFR exon 19 or exon 21 mutation who receive amivantamab with platinum-based chemotherapy after having been treated with osimertinib (with or without chemotherapy), also through an early access program. The main question the study wants to answer is: How long can the combination of amivantamab and chemotherapy keep the cancer from coming back or getting worse in these two groups of people? People already receiving amivantamab and chemotherapy for NSCLC through an early access program may be included. They will continue to be followed by their usual oncologist as part of their normal medical care. The study will simply collect their medical information from March 21, 2024 to October 21, 2025. No extra tests or procedures are required. This is an observational study, carried out by the GFPC and partner centers in France.

This description comes directly from the study's public registry record.

Talk to the study team

Prof. Laurent Greillier  ·  +33 4 73 98 39 86  ·  a.boucheix@g-f-p-c.org

Soizic Ferlandin  ·  +33 6 63 22 47 89  ·  soizic_ferlandin@yahoo.fr

Always discuss trial participation with your own doctor first.

Locations (16)

CH du Pays d Aix - Service des Maladies RespiratoiresAix-en-Provence, FranceRecruiting
APHP Hôpital AvicennesBobigny, FranceRecruiting
Hôpital Louis PradelBron, FranceActive Not Recruiting
Pneumologie Centre François BaclesseCaen, FranceActive Not Recruiting
Pneumologie Centre Hospitalier Intercommunal de CréteilCréteil, FranceRecruiting
Hôpital A. MignotLe Chesnay, FranceRecruiting
Pneumologie Hôpital CalmetteLille, FranceRecruiting
Pneumologie Hôpital privé Jean MermozLyon, FranceRecruiting
Centre Léon BérardLyon, FranceRecruiting
Hôpital NordMarseille, FranceRecruiting
CHRU de NancyNancy, FranceActive Not Recruiting
Centre Antoine LacassagneNice, FranceActive Not Recruiting

+ 4 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07563205